616 related articles for article (PubMed ID: 37129252)
1. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.
Kaufmann B; Seyfried N; Hartmann D; Hartmann P
Am J Physiol Gastrointest Liver Physiol; 2023 Jul; 325(1):G42-G61. PubMed ID: 37129252
[TBL] [Abstract][Full Text] [Related]
2. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
4. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses.
Mahapatro A; Bawna F; Kumar V; Daryagasht AA; Gupta S; Raghuma N; Moghdam SS; Kolla A; Mahapatra SS; Sattari N; Amini-Salehi E; Nayak SS
Clin Nutr ESPEN; 2023 Oct; 57():475-486. PubMed ID: 37739694
[TBL] [Abstract][Full Text] [Related]
6. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
Hartmann P; Schnabl B
Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682
[TBL] [Abstract][Full Text] [Related]
7. The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.
Amini-Salehi E; Hassanipour S; Keivanlou MH; Shahdkar M; Orang Goorabzarmakhi M; Vakilpour A; Joukar F; Hashemi M; Sattari N; Javid M; Mansour-Ghanaei F
Nutr Rev; 2024 May; 82(6):815-830. PubMed ID: 37550264
[TBL] [Abstract][Full Text] [Related]
8. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Rong L; Ch'ng D; Jia P; Tsoi KKF; Wong SH; Sung JJY
J Gastroenterol Hepatol; 2023 Oct; 38(10):1682-1694. PubMed ID: 37409560
[TBL] [Abstract][Full Text] [Related]
9. The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.
Li S; Liu J; Wang Z; Duan F; Jia Z; Chen X; Li S
Front Public Health; 2022; 10():862266. PubMed ID: 35958869
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.
Sharpton SR; Maraj B; Harding-Theobald E; Vittinghoff E; Terrault NA
Am J Clin Nutr; 2019 Jul; 110(1):139-149. PubMed ID: 31124558
[TBL] [Abstract][Full Text] [Related]
12. The synbiotic combination of probiotics and inulin improves NAFLD though modulating gut microbiota.
Zhang C; Fang T; Shi L; Wang Y; Deng X; Wang J; Zhou Y
J Nutr Biochem; 2024 Mar; 125():109546. PubMed ID: 38072206
[TBL] [Abstract][Full Text] [Related]
13. The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.
Vakilpour A; Amini-Salehi E; Soltani Moghadam A; Keivanlou MH; Letafatkar N; Habibi A; Hashemi M; Eslami N; Zare R; Norouzi N; Delam H; Joukar F; Mansour-Ghanaei F; Hassanipour S; Samethadka Nayak S
Nutr Diabetes; 2024 May; 14(1):25. PubMed ID: 38729941
[TBL] [Abstract][Full Text] [Related]
14. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
15. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS.
Barengolts E
Endocr Pract; 2016 Oct; 22(10):1224-1234. PubMed ID: 27409822
[TBL] [Abstract][Full Text] [Related]
16. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
[TBL] [Abstract][Full Text] [Related]
19. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
20. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach.
Sangouni AA; Ghavamzadeh S
Diabetes Metab Syndr; 2019; 13(5):2917-2922. PubMed ID: 31425956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
